Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 2
1965 1
1967 1
1969 2
1970 1
1972 2
1973 1
1975 2
1976 5
1977 3
1978 8
1979 6
1980 8
1981 15
1982 38
1983 106
1984 220
1985 231
1986 255
1987 286
1988 355
1989 306
1990 395
1991 410
1992 429
1993 494
1994 500
1995 572
1996 612
1997 720
1998 852
1999 950
2000 1076
2001 1176
2002 1470
2003 1610
2004 1790
2005 2123
2006 2304
2007 2591
2008 2732
2009 2988
2010 3241
2011 3568
2012 3833
2013 4287
2014 4576
2015 4630
2016 4754
2017 4810
2018 4794
2019 5035
2020 5369
2021 5506
2022 5636
2023 5352
2024 1665

Text availability

Article attribute

Article type

Publication date

Search Results

84,588 results

Results by year

Filters applied: . Clear all
Page 1
Genetically identified mediators associated with increased risk of stroke and cardiovascular disease in individuals with autism spectrum disorder.
Jin T, Huang W, Pang Q, Cao Z, Xing D, Guo S, Zhang T. Jin T, et al. J Psychiatr Res. 2024 Apr 16;174:172-180. doi: 10.1016/j.jpsychires.2024.04.027. Online ahead of print. J Psychiatr Res. 2024. PMID: 38640796
However, the causal association between ASD and the risk of stroke and CVD remains unclear. To validate this, we performed two-sample Mendelian randomization (MR) and two-step mediation MR analyses, using relevant genetic variants sourced from the largest genome-wide assoc …
However, the causal association between ASD and the risk of stroke and CVD remains unclear. To validate this, we performed two-sample Mendel …
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
Drake T, Landsteiner A, Langsetmo L, MacDonald R, Anthony M, Kalinowski C, Ullman K, Billington CJ, Kaka A, Sultan S, Wilt TJ. Drake T, et al. Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1490. Online ahead of print. Ann Intern Med. 2024. PMID: 38639549 Review.
BACKGROUND: Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes. PURPOSE: To evaluate the effectiveness, comparative effectiveness, and harms of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like pe …
BACKGROUND: Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes. PURPOSE …
Prediction of glycosylated hemoglobin level in patients with cardiovascular diseases and type 2 diabetes mellitus with respect to anti-diabetic medication.
Ikramov A, Mukhtarova S, Trigulova R, Alimova D, Abdullaeva S. Ikramov A, et al. Front Endocrinol (Lausanne). 2024 Apr 4;15:1305640. doi: 10.3389/fendo.2024.1305640. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38638138 Free PMC article.
Blood glycosylated hemoglobin level can be affected by various factors in patients with type 2 diabetes and cardiovascular diseases. Frequent measurements are expensive, and a suitable estimation method could improve treatment outcomes. ...CONCLUSION: The resulting …
Blood glycosylated hemoglobin level can be affected by various factors in patients with type 2 diabetes and cardiovascular dis …
Twenty-Four week Taichi training improves pulmonary diffusion capacity and glycemic control in patients with Type 2 diabetes mellitus.
Liu X, Zhu H, Peng Y, Liu Y, Shi X. Liu X, et al. PLoS One. 2024 Apr 18;19(4):e0299495. doi: 10.1371/journal.pone.0299495. eCollection 2024. PLoS One. 2024. PMID: 38635535 Free PMC article.
This study evaluated the effect of 24-week Taichi training and Taichi plus resistance band training on pulmonary diffusion capacity and glycemic control in patients with Type 2 diabetes mellitus (T2DM). Forty-eight patients with T2DM were randomly
This study evaluated the effect of 24-week Taichi training and Taichi plus resistance band training on pulmonary diffusion capacity and glyc …
Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review.
Lava SAG, Laurence C, Di Deo A, Sekarski N, Burch M, Della Pasqua O. Lava SAG, et al. Paediatr Drugs. 2024 Apr 18. doi: 10.1007/s40272-024-00623-z. Online ahead of print. Paediatr Drugs. 2024. PMID: 38635113
INTRODUCTION: In adults, sodium-glucose cotransporter type 2 inhibitors have revolutionised the treatment of type 2 diabetes mellitus, heart failure, and chronic kidney disease. ...For the two randomised controlled trials on type
INTRODUCTION: In adults, sodium-glucose cotransporter type 2 inhibitors have revolutionised the treatment of type 2
Safety of Linagliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Aljohani H, Alrubaish FS, Alghamdi WM, Al-Harbi F. Aljohani H, et al. Ther Innov Regul Sci. 2024 Apr 18. doi: 10.1007/s43441-024-00637-2. Online ahead of print. Ther Innov Regul Sci. 2024. PMID: 38634983 Review.
BACKGROUND: Linagliptin is an oral dipeptidyl peptidase DPP-4 inhibitor, which is indicated for the treatment of Type 2 diabetes mellitus (T2DM) as monotherapy or add-on to therapy with other hypoglycemic drugs. OBJECTIVES: We aimed to summarize the ev …
BACKGROUND: Linagliptin is an oral dipeptidyl peptidase DPP-4 inhibitor, which is indicated for the treatment of Type 2 dia
The health-related quality of life of patients with type 1 and type 2 diabetes mellitus: a meta-analysis.
Fidan C, Ağırbaş İ. Fidan C, et al. Endocrine. 2024 Apr 17. doi: 10.1007/s12020-024-03824-1. Online ahead of print. Endocrine. 2024. PMID: 38632164
PURPOSE: We need to know about the health-related quality of life (HRQoL) of patients with diabetes mellitus (DM) to assess their health outcomes. Quantitative studies have discussed whether patients with Type 1 DM (T1DM) have better HRQoL than those with …
PURPOSE: We need to know about the health-related quality of life (HRQoL) of patients with diabetes mellitus (DM) to assess th …
Long-term exposure to ambient air pollution and risk of microvascular complications among patients with type 2 diabetes: a prospective study.
Wang B, Sun Y, Zhang K, Wang Y, Tan X, Wang N, Lu Y. Wang B, et al. Int J Epidemiol. 2024 Apr 11;53(3):dyae056. doi: 10.1093/ije/dyae056. Int J Epidemiol. 2024. PMID: 38632038
BACKGROUND: Patients with type 2 diabetes (T2D) may disproportionately suffer the adverse cardiovascular effects of air pollution, but relevant evidence on microvascular outcome is lacking. ...
BACKGROUND: Patients with type 2 diabetes (T2D) may disproportionately suffer the adverse cardiovascular effects of air pollut …
Genetic risk of type 2 diabetes modifies the association between lifestyle and glycemic health at 5 years postpartum among high-risk women.
Tieu S, Koivusalo S, Lahti J, Engberg E, Laivuori H, Huvinen E. Tieu S, et al. BMJ Open Diabetes Res Care. 2024 Apr 17;12(2):e003942. doi: 10.1136/bmjdrc-2023-003942. BMJ Open Diabetes Res Care. 2024. PMID: 38631819 Free PMC article. Clinical Trial.
INTRODUCTION: Lifestyle interventions are effective in preventing type 2 diabetes, but genetic background may influence the individual response. ...The PRS for type 2 diabetes was not associated with glycemic abnormalities, nor was HLS in the total stu …
INTRODUCTION: Lifestyle interventions are effective in preventing type 2 diabetes, but genetic background may influence the in …
Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.
Kittipibul V, Cox ZL, Chesdachai S, Fiuzat M, Lindenfeld J, Mentz RJ. Kittipibul V, et al. J Am Coll Cardiol. 2024 Apr 23;83(16):1568-1578. doi: 10.1016/j.jacc.2024.01.040. J Am Coll Cardiol. 2024. PMID: 38631776 Review.
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure hospitalization in patients with heart failure, as well as adv …
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type
84,588 results
You have reached the last available page of results. Please see the User Guide for more information.